A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy


Berrak S. G. , Ozdemir N., Bakirci N. , Turkkan E., Canpolat C., Beker B., et al.

SUPPORTIVE CARE IN CANCER, cilt.15, ss.1163-1168, 2007 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 15 Konu: 10
  • Basım Tarihi: 2007
  • Doi Numarası: 10.1007/s00520-007-0242-y
  • Dergi Adı: SUPPORTIVE CARE IN CANCER
  • Sayfa Sayısı: ss.1163-1168

Özet

Background Granisetron is a safe and effective prophylaxis for nausea and vomiting associated with moderate to highly emetogenic chemotherapy. Few trials have been conducted to determine the optimal effective dose of granisetron in children with cancer. The objective of this report was to compare two doses of granisetron in patients with optic pathway tumors receiving moderately emetogenic doses of carboplatin.